On November 20, Intellia Therapeutics rose 5.24% in Regular Trading, trading at $10.21/share, with turnover of $12.47 million. The move was linked to investor focus on the completion of enrollment in the MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, alongside a reiterated Buy rating and a $49 price target.
Earlier company updates said MAGNITUDE-2 enrollment had been completed and cash stood at $614.8 million, which management expects to fund operations at least into 2028. That support came despite weaker quarterly figures reported earlier this month, including EPS of $0.91 loss versus a $0.80 loss estimate and revenue of $7.163 million versus a $10.461 million estimate, leaving the stock caught between pipeline progress and near-term earnings pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)